干扰素λ的药理学及临床应用研究进展

摘要

干扰素λ(IFN-λ)为一类新发现的Ⅲ型干扰素,隶属于Ⅱ型细胞因子家族,其异二聚体功能性受体复合物IL-28Rα/IL- 10Rβ具有组织学分布特异性.IFN-λ主要通过JAK-STAT途径发挥其药理学活性,包括抗病毒、抗增殖及免疫调节作用.在Ⅰ期及Ⅱ期临床试验中IFN-λ产生的不良反应较IFN-α为少,因此在治疗肝炎及特异性抗肿瘤方面可能具有良好的应用前景.本文主要针对近年来IFN-λ的药理学活性及临床应用进行总结.%Type Ⅲ interferons(IFN-λs),including IFN-λ1,IFN-λ2 and IFN-λ3,are a newly discovered type Ⅲ interferons group belonging to type II cytokines family. The IFN-λ receptor (IFN-λR) complexes IL-28Rα/ IL-10Rβ are highly specific in histological distribution. IFN-λs signal through the IFN-λR complexes and activate JAK-STAT pathways to induce the pharmacological activities similar to IFN-a, including antivirus, antitumor and immune response. Due to the specificity of receptor's distribution, the side effects of IFN-λs are weaker than those of IFN-α. Moreover, IFN-λs have potential prospects in tumor therapy. In this review, we summarize the recent research advances in IFN-λs' pharmacological characteristics and their clinical uses.